Publications
292
Citations
8,016
Est. group size
~34
Recurring co-author estimate
Active years
19
Publishing since 2008
Uma Borate is a physician-researcher focused on blood cancers, especially acute myeloid leukemia (AML, a fast-growing cancer of blood-forming cells) and myelodysplastic syndromes (MDS, disorders where the bone marrow fails to make healthy blood cells). Their work centers on running and reporting clinical trials that test new drugs and drug combinations, often targeting specific genetic mutations (like FLT3, IDH1/2, TP53, NPM1) found in these diseases, as well as efforts to standardize diagnosis and improve access to clinical trials for patients.
Publication output has grown substantially over the last decade, rising from single digits in 2017 to over 80 in 2025, indicating an accelerating and currently very active publication pace.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia
Blood Neoplasia · 2026
- Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Blood · 2025
- Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Blood Advances · 2025
- A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Cancer Research Communications · 2025
- Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Archives of Pathology & Laboratory Medicine · 2025
- Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations
Frontiers in Hematology · 2025
- Phase 3 study of either ivosidenib monotherapy or azacitidine monotherapy in patients with IDH1-mutant myelodysplastic syndromes who are hypomethylating agent naive (PyramIDH).
Journal of Clinical Oncology · 2025
- Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
Blood · 2025
- Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia
Blood · 2025
- Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia
Blood · 2025
- Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study
Blood · 2025
- Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement
Blood · 2025
- Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
Blood · 2025
- A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)
Blood · 2025
- Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
2025
- Blood×100
- Clinical Lymphoma Myeloma & Leukemia×26
- Blood Advances×12
- Journal of Clinical Oncology×12
- HemaSphere×4
- Alice S. Mims
Medicine · The Ohio State University
- Krzysztof Mrózek
Medicine · The Ohio State University
- Deedra Nicolet
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
- Priyanka Mehta
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile